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OBJECTIVES We investigated the development of nitrate tolerance after continuous exposure to nitroglyc-
erin (GTN) as compared with pentaerythritol tetranitrate (PETN) in humans.
BACKGROUND Sustained therapy with GTN causes tolerance and has been associated with increased
production of free oxygen radicals by the endothelium. Pentaerythritol tetranitrate is an
organic nitrate that has been used in the therapy of angina. There have been no investigations
concerning the development of tolerance to PETN in humans. Animal investigations
suggested that continuous therapy with PETN does not cause increased free radical
production or hemodynamic tolerance.
METHODS We randomized 30 healthy volunteers to continuous GTN (0.6 mg/h/24 h), long-acting
PETN (60 mg orally three times a day) or no treatment (control group) for seven days. We
studied systemic blood pressure responses and venous volume responses to GTN with
strain-gauge plethysmography. The levels of cytotoxic aldehydes and isoprostanes were
measured as markers of free radical-mediated lipid peroxidation.
RESULTS Tolerance, as demonstrated by blood pressure and forearm plethysmography, developed in the
GTN group and was absent in the PETN group (p , 0.05). Therapy with GTN was
associated with a significant increase in plasma markers of lipid peroxidation. This response
was not observed in those treated with PETN (isoprostanes: control: 38 6 5; GTN: 59 6 6;
PETN: 38 6 3 mg/ml; p , 0.005).
CONCLUSIONS Treatment with PETN does not cause tolerance and is not associated with evidence of
increased free radical production. (J Am Coll Cardiol 2001;38:854–9) © 2001 by the
American College of Cardiology
Organic nitrates have been used for more than 100 years in
the treatment of myocardial ischemia and congestive heart
failure, but the development of tolerance still represents a
limitation to their use. Tolerance can be defined as loss of
nitrate effects on symptomatic benefit or hemodynamic
parameters after continuous exposure. There is clear evi-
dence that tolerance develops to the effects of nitroglycerin
(GTN) as well as with isosorbide mononitrate and dinitrate
when they are administered in a fashion that leads to
sustained therapeutic plasma concentrations.
Pentaerythritol tetranitrate (PETN) is an organic nitrate
that has been used extensively in Europe for many years.
Although this compound has been available in North
America, its clinical application in that market has been
limited. Investigations concerning the clinical efficacy of this
nitrate drug have been limited, and there have been no
human studies addressing the issue of tolerance during
therapy with this compound. Interestingly, recent animal
data suggest that PETN might have antiatherosclerotic
effects (1–3) and that continuous exposure to this compound
does not cause tolerance (4). Furthermore, animal experi-
ments have suggested that PETN therapy is not associated
with increased free radical production by the endothelium
(3,5,6), a phenomenon that has now been repeatedly dem-
onstrated with GTN (7–9). This study was designed to
investigate the hemodynamic and biochemical effects of
continuous therapy with PETN as compared with transder-
mal GTN or no treatment.
METHODS
Study population. Thirty healthy male nonsmoking vol-
unteers (age range 19 to 39 years) were included in the
study. Subjects were asked to abstain from medications or
supplemental vitamins during the study period and from
alcohol or caffeine-containing beverages for at least 12 h
before each study visit. A 3-h fasting period preceded visits.
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The study protocol was approved by the University of
Toronto Human Subjects Review Committee, and written
informed consent was obtained in all cases.
Study protocol. VISIT 1. On visit 1, after subjects were
screened for admission into the study, standing arterial
blood pressure and heart rate were measured using an
automatic calibrated sphygmomanometer (Critikon Com-
pany LLC, Tampa, Florida). All results represented the
average of three different measurements taken at 1-min
intervals. Forearm venous blood volume (FBV) and re-
sponses to sublingual GTN (0.6 mg) were then recorded
using forearm venous occlusion mercury-in-silastic strain-
gauge plethysmography. The details of this technique are
described in the following text.
VISIT 2. One week later, subjects arrived at our laboratory at
the same time as for visit 1. Standing blood pressure and
heat rate measurements were repeated. The subjects were
then randomized in an investigator-blind, parallel design to
receive transdermal GTN 0.6 mg/h (GTN group), PETN
60 mg orally every 8 h (PETN group) or no treatment
(control group). Nitroglycerin patches were obtained from
Novartis Pharmaceuticals (Dorval, Que´bec, Canada);
PETN pills were obtained from Dexo S.A. (Nanterre,
France). The first dose was administered in the laboratory,
and repeat blood pressure and heart rate measurements were
taken 3 h after the initial dose in order to measure the
response to acute administration. Subjects randomized to
nitrates were instructed by the randomizing nurse to wear
the patch continuously, changing it every morning at the
same time. Subjects were instructed not to reveal their
treatment allocation to the investigator. The randomizing
nurse did not take part in any other aspect of study
procedures or data analysis. Subjects randomized to PETN
were asked to take 60 mg PETN orally every 8 h for the
following six days. This dosing regimen of PETN was
chosen in order to prevent a nitrate-free interval. The
half-life of PETN and its metabolites in humans is reported
to be 8 h (10), and the formulation used was a long-acting
preparation designed to be given twice daily. Subjects were
then given a seven-day supply of the assigned study drug
and discharged home.
VISIT 3. After seven days of continuous treatment, subjects
returned to the laboratory, and blood samples were ob-
tained. Blood pressure and heart rate were taken again with
the same procedure, and FBV was measured as in visit 1.
Visits were conducted at mid-day in order to ensure that
the subjects had received their morning dose of the study
drug.
Measurement of FBV. Forearm venous blood volume at
baseline and in response to sublingual GTN was measured
using strain-gauge venous occlusion plethysmography as
previously reported (11). Briefly, hand circulation was ex-
cluded by inflating a wrist cuff to 200 mm Hg during
measurement periods. The upper arm cuff was inflated to
30 mm Hg and was kept inflated until a plateau was
reached, representing the baseline FBV. Once a baseline
measure had been taken, 0.6 mg sublingual GTN were
administered, and FBV was recorded for at least 10 min
until a new plateau had been reached. Forearm venous blood
volume was measured in ml/100 ml of forearm tissue, and
the change in FBV in response to acute administration of
0.6 mg sublingual GTN was expressed as percent from
baseline value. Forearm plethysmographic measurements
were made using a Hokanson EC4 Plethysmograph (D. E.
Hokanson Inc., Bellevue, Washington) and recorded on a
multichannel recorder (Gould 5900 Card Cage, Gould
Instrument Systems, Inc., Valley View, Ohio). All measure-
ments and visits were performed in a quiet, temperature and
humidity-controlled laboratory.
Markers of oxidative stress. The levels of cytotoxic alde-
hydes and isoprostanes were determined as previously de-
scribed (12). Total lipid extract of plasma was prepared by
the method of Folch et al. (13). The total lipid extract was
chromatographed on a normal phase 5-mm Spherisorb
high-pressure liquid chromatography (HPLC) column
(250 3 4.6 mm inner diameter, Alltech Associates, Deer-
field, Illinois). The column was installed into a Hewlett-
Packard (Andover, Massachusetts) model 1090 liquid chro-
matograph and eluted with a linear gradient of 100% solvent
A (chloroform/methanol/30% ammonium hydroxide, 80:
19.5:0.5, by volume) to 100% solvent B (chloroform/
methanol/water/30% ammonium hydroxide, 60:34:5.5:0.5,
by volume) in 14 min and then at 100% solvent B for 10 min
(14). The flow was set at 1 ml/min. The peaks were
monitored by on-line electrospray mass spectrometry (ES/
MS). Normal phase HPLC with ES/MS was performed by
splitting the HPLC flow by 1/50, resulting in 20 ml/ml being
admitted to a Hewlett-Packard model 5988B quadrupole mass
spectrometer equipped with a nebulizer-assisted electrospray
interface (HP 59987A) (15). Arachidoyl phosphatidylcholine
was added as internal standard. This method allowed us to
measure the levels of four cytotoxic aldehydes (16:0-C5
aldehyde phosphatidylcholine, 18:0-C5 aldehyde phos-
phatidylcholine, 16:0-C9 aldehyde phosphatidylcholine and
18:0-C9 aldehyde phosphatidylcholine) and three isopros-
tanes (16:0-E2/D2 isoprostane phosphatidylcholine, 16:
0-F2 isoprostane phosphatidylcholine and 18:0-E2/D2 iso-
prostane phosphatidylcholine). All of these chemical
compounds represent the result of nonenzymatic lipid
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ES/MS 5 on-line electrospray mass spectrometry
FBV 5 forearm venous blood volume
GTN 5 nitroglycerin
HPLC 5 high-pressure liquid chromatography
NO 5 nitric oxide
PETN 5 pentaerythritol tetranitrate
ROS 5 reactive oxygen species
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peroxidation and, as such, are felt to be specific markers of
free radical-mediated lipid injury (16–18).
Statistical analysis. All variables were normally distributed
(Shapiro-Wilk). Changes in blood pressure and heart rate
within groups were evaluated using a one-way analysis of
variance (ANOVA) for repeated measures. The Bonferroni
test was used for multiple comparisons. Differences in
venous volume responses between study days within each
group were compared using a paired t test. Between group
differences in the response of venous blood volume were
compared using analysis of covariance. Oxidative stress data
were analyzed with a one-way ANOVA for nonrepeated
measures. All analyses were performed in SAS version 8.1
(SAS Institute Inc., Cary, North Carolina). All differences
were considered to be significant when p ,0.05. All results
are expressed as mean 6 SE.
RESULTS
Blood pressure and heart rate responses. All results are
presented in Table 1. Standing heart rate and systolic blood
pressure did not differ among groups at baseline. Blood
pressure did not change significantly in the control group
throughout the study.
Transdermal GTN caused a significant fall in standing
systolic blood pressure 3 h after patch application. On visit
3, after sustained therapy with transdermal GTN, standing
systolic blood pressure had returned to baseline values,
indicating the development of tolerance (p , 0.05). In the
PETN group, a significant decrease in systolic blood pres-
sure was observed 3 h after acute administration (p , 0.05),
and this decrease was still present after continuous therapy
(p , 0.05 vs. before randomization, p 5 NS vs. after acute
administration).
Similar results were obtained with heart rate. Heart rate
increased 3 h after the first administration of GTN and
returned to lower levels after one week of treatment (p ,
0.05). In the PETN group, heart rate increased after acute
administration and remained higher after continuous expo-
sure (p , 0.05). There was no change in the control group.
FBV responses. Venous blood volume responses and the
results of the statistical analysis are reported in Table 2 and
Figure 1. Venous blood volume (ml/100 ml of forearm
volume) increased similarly among groups before random-
ization in response to sublingual GTN. In the control
group, the increase in FBV in response to sublingual GTN
was similar at each visit. Continuous treatment with trans-
dermal GTN caused a significant decrease in both absolute
and percent increase in volume in response to sublingual
GTN compared with before randomization (p , 0.05). In
the PETN group, after continuous therapy, the response to
sublingual GTN was similar to that obtained on visit 1 (p 5
NS). The analysis of covariance revealed that the differences
in absolute, delta and percent changes in blood volume
between groups on visit 3 were significant (p , 0.05).
Markers of oxidative stress. Plasma levels of cytotoxic
aldehydes are expressed individually and as the sum of the
four compounds measured. After the treatment period, in
the GTN group the plasma concentrations of the aldehydes
were significantly higher than those in the control and
PETN groups. Furthermore, there was no difference ob-
served in the plasma concentration of these compounds
when values in the control and PETN groups were com-
pared. (p , 0.02; Table 3, Fig. 2). Similar results were
obtained with isoprostanes (p , 0.005, Table 3, Fig. 3).
Individual values for each compound are also reported in
Table 3.
Table 1. Blood Pressure and Heart Rate Responses to Study
Drug in the Three Groups
Control GTN PETN
Blood pressure
Before randomization 116 6 2 115 6 3 116 6 2
After acute administration 114 6 2 104 6 3* 107 6 3*
After chronic administration 116 6 3 113 6 3 109 6 3*
Heart rate
Before randomization 82 6 2 76 6 4 74 6 4
After acute administration 79 6 3 88 6 6* 82 6 3*
After chronic administration 82 6 3 80 6 5 80 6 3*
*p , 0.05 compared with before randomization, one-way analysis of variance.
GTN 5 nitroglycerin; PETN 5 pentaerythritol tetranitrate.
Table 2. Forearm Blood Volume Results: Baseline Values and
Absolute Increases in Response to Sublingual GTN
Control GTN PETN
Before randomization
Baseline 2.57 6 0.34 2.70 6 0.29 2.39 6 0.24
Delta after sublingual GTN 0.60 6 0.09 0.79 6 0.17 0.71 6 0.13
After randomization
Baseline 1.65 6 0.21 2.44 6 0.29 2.26 6 0.30
Delta after sublingual GTN 0.54 6 0.08 0.43 6 0.06* 0.68 6 0.10†
*p , 0.05 compared with before randomization (paired t test); †p , 0.05 compared
with GTN group (analysis of covariance).
GTN 5 nitroglycerin; PETN 5 pentaerythritol tetranitrate.
Figure 1. Percent change in forearm blood volume in response to 0.6 mg
sublingual nitroglycerin (GTN) in the three groups. *p , 0.05 compared
with GTN group, analysis of covariance. †p , 0.05 compared with before
randomization, paired t test; p 5 NS before randomization versus after
chronic administration for control and pentaerythritol tetranitrate (PETN)
groups, paired t test. Open bar 5 before randomization; closed bar 5 after
chronic administration.
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DISCUSSION
Evidence for a role of oxidative stress in nitrate tolerance.
Nitrate tolerance remains a major limiting factor in the
treatment of congestive heart failure and coronary artery
disease. The mechanism of nitrate tolerance remains elusive
and is probably multifactorial. Traditionally, reduced bio-
conversion of nitrates was implicated (19), although later
animal experiments did not support that view (20). Most
recently, Sage et al. (21), using human vascular tissue,
proposed that reduced bioconversion could be involved,
especially in the venous circulation. Although a unifying
hypothesis of nitrate tolerance has remained elusive over the
past several years, a great deal of research has focused on the
role of the endothelium in the development of nitrate
tolerance. A number of reports have suggested that exposure
to GTN is associated with increased production of reactive
oxygen species (ROS) by the endothelium and that this
response may play a role in the development of tolerance.
Several reports have confirmed that GTN therapy leads to
endothelial dysfunction and increased production of super-
oxide anion (7–9). An increased production of superoxide
anion has also been demonstrated in the presence of all risk
factors for coronary artery disease, and its negative effects on
vasomotion have been extensively investigated (22).
Interestingly, Mu¨nzel et al. (8) demonstrated that the
endothelium plays an obligatory role in the development of
tolerance, potentially through the synthesis of oxygen free
radicals. It has been demonstrated that superoxide anion can
bind to nitric oxide (NO), which mediates the activity of
nitrates, thus reducing its bioavailability. The end product
of the reaction is peroxynitrite (23), which, at doses in the
micromolar range, induces vasoconstriction (24) and inhib-
its the uptake of levo-arginine and the activity of endothelial
NO synthase (25,26). Thus, it appears that the bioavailabil-
ity of NO, both endogenous and delivered by GTN, might
depend on the GTN-induced local formation of superoxide
anion.
Results from ex vivo animal studies demonstrate that
PETN does not induce vascular tolerance (4) and does not
cause an increase in vascular production of ROS as was seen
with GTN therapy. One in vitro study provides a potential
mechanism, where PETN induced the production of fer-
ritin, a potent antioxidant protein, in endothelial cells (27).
Summary of results. The results of this study confirm that
PETN, as compared with GTN, does not induce hemody-
namic tolerance or evidence of oxidative stress in humans in
vivo. To the best of our knowledge, this is the first human
study to examine the impact of sustained PETN therapy on
the development of tolerance.
Figure 2. Cytotoxic aldehydes (total of the four compounds measured)
after continuous treatment in the three groups. *p , 0.02 compared with
control and pentaerythritol tetranitrate (PETN), analysis of variance.
GTN 5 nitroglycerin.
Figure 3. Isoprostanes (total of the three compounds measured) after
continuous treatment. *p , 0.005 compared with control and pentaeryth-
ritol tetranitrate (PETN), analysis of variance. GTN 5 nitroglycerin.
Table 3. Aldehydes and Isoprostanes: Individual Levels and Totals of the Compounds Measured
16:0-C5 Ald PC 18:0-C5 Ald PC 16:0-C9 Ald PC 18:0-C9 Ald PC Total
Aldehydes
Control 2.6 6 0.2 1.9 6 0.5 1.0 6 0.2 1.2 6 0.2 6.7 6 0.9
GTN 3.3 6 0.4 2.7 6 0.5* 2.0 6 0.4* 2.7 6 0.5* 10.7 6 0.8†
PETN 3.7 6 1.2 0.8 6 1.2 0.9 6 0.2 1.0 6 0.4 6.4 6 1.5
16:0-F2 IsoP PC 16:0-E2/D2 IsoP PC 18:0-F2 IsoP PC Total
Isoprostanes
Control 10.2 6 1.2 18.1 6 3.3 9.7 6 0.7 38.0 6 4.5
GTN 19.6 6 2.8* 25.8 6 3.3* 13.7 6 2.4* 59.1 6 5.9‡
PETN 11.4 6 1.6 19.1 6 1.7 7.8 6 0.6 38.3 6 2.9
*p , 0.05; †p , 0.02; ‡p , 0.005 compared with control and PETN, one-way analysis of variance.
Ald PC 5 aldehyde phosphatidylcholine; GTN 5 nitroglycerin; IsoP PC 5 isoprostane phosphatidylcholine; PETN 5
pentaerythritol tetranitrate. All values in mg/ml.
857JACC Vol. 38, No. 3, 2001 Jurt et al.
September 2001:854–9 PETN versus GTN
Blood pressure measurements demonstrate that, after
continuous treatment, PETN continues to have a significant
hemodynamic effect, while GTN does not. This indicates
that tolerance does not develop to the systemic hemody-
namic effects of PETN. The venous volume responses
demonstrate that cross-tolerance to GTN, given acutely,
does not develop during PETN therapy.
Our biochemical data show that GTN induces a signif-
icantly higher production of ROS, while, after PETN
treatment, the levels of oxidized lipids do not differ from
normal.
Importance of cytotoxic aldehydes and isoprostanes. Iso-
prostanes and cytotoxic aldehydes are products of oxidative
modification of membrane-bound or low-density lipoprotein-
bound phospholipids through a free radical catalyzed reac-
tion (16–18). Although the importance of these compounds
is still not completely clear, it has been suggested that they
may have adverse effects on endothelial and smooth muscle
cell function (28). Increased levels of isoprostanes have been
detected in the presence of many risk factors for cardiovas-
cular disease, including smoking, diabetes mellitus and
hypercholesterolemia (29–31). Furthermore, some isopros-
tane species have been shown to have potent vasoconstrictor
effects (32) as well as significant antinatriuretic effects (33),
which might contribute to the phenomenon of plasma
expansion that follows continuous GTN exposure and to
tolerance itself. The importance of free radical production in
the development of tolerance is supported by the results of
studies in which antioxidant supplementation prevented
tolerance or reduced free radical production during nitrate
therapy (6,34,35). The vasoconstrictor activities of isopros-
tanes might also be implicated in the development of
tolerance and supersensitivity to vasoconstrictor stimuli (36)
and in the pathophysiology of rebound phenomena (37).
Furthermore, it has been hypothesized that isoprostanes,
due to the stiffness of their molecular structure, may
significantly affect the fluidity and the integrity of cell
membrane bilayers (18).
Previous findings from our laboratory argued against a
role for oxidative stress in the pathogenesis of nitrate
tolerance (11). In this report, the levels of a short chain
isoprostane, 8-iso-PGF2a, were not modified by GTN
treatment. We believe that our present observations may be
more reliable. Long-chain isoprostanes are less water soluble
and more stable than short-chain species and, thus, may be
more sensitive as markers of lipid peroxidation. In our
previous report (11), tolerance to GTN was not restored
with the acute administration of vitamin C. We do not
believe that this is entirely inconsistent with the present
findings. If the mechanism underlying nitrate tolerance is
mediated by oxidative stress, antioxidant supplementation
might be able to prevent this process while being unable to
reverse it.
Study limitations. In this study, the effect of an oral
formulation of PETN was compared with that of transder-
mal GTN. Indeed, our study represents a follow-up of other
animal studies comparing GTN to PETN (1–4). Nitroglyc-
erin given orally is poorly bioavailable, and there is essen-
tially no evidence concerning the development of tolerance
or even the acute clinical effectiveness of GTN in this
formulation. On the other side, PETN is not available as a
transdermal preparation. A formulation and dosage regimen
that was designed to maintain therapeutic plasma PETN
concentrations throughout the 24-h period was chosen.
Future studies are now needed to compare the effects of
PETN with those of other orally available nitrates, such as
isosorbide dinitrate and mononitrate.
Importance of the present findings. We believe our find-
ings to have potential, direct clinical relevance. First, this
study demonstrates the absence of tolerance to PETN in a
human model. This finding warrants a reconsideration of
the utility of PETN in clinical practice, and further clinical
studies investigating the effects of PETN versus GTN in
the setting of heart failure or angina are now required.
Second, we demonstrated that the appearance of tolerance
to GTN is associated with the production of ROS that are
able to oxidize membrane lipids. These findings have
potential implications concerning the long-term effects of
therapy with GTN.
Understanding the nature of the biochemical responses to
nitrates at the level of the endothelium appears to be
providing clear insights into the mechanism of tolerance. A
series of investigations now suggests that GTN causes
abnormalities in NOS function that lead to increased ROS
production. Further studies are required to investigate the
mechanisms of these changes and to develop strategies to
counteract them. Our observations with PETN suggest that
there are important nitrate-specific differences in these
responses.
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